Access cutting-edge bladder cancer treatment through this clinical trial at a research site in Lancaster. Study-provided care at no cost to qualified participants.
Access bladder cancer specialists in Lancaster at no cost
This study follows strict safety protocols and ethical guidelines
All study-related bladder cancer treatment provided free
This phase II trial studies how well Pemigatinib (an orally administered inhibitor of fibroblast growth factor receptors 1, 2, and 3) works in non-muscle invasive bladder cancer (NMIBC) patients with recurrent tumors and a prior history of low- or intermediate-risk NMIBC tumors. Participants will receive pemigatinib for 4-6 weeks prior to standard of care transurethral resection of bladder tumor (TURBT).
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Check if you qualify for this bladder cancer clinical trial in Lancaster, PA
If you're searching for bladder cancer treatment options in Lancaster, PA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Lancaster research site is actively enrolling participants for this clinical trial. You'll receive care from experienced bladder cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.